Related Experiment Video
Updated: Feb 7, 2026

Development and Characterization of Fusidic Acid-Loaded Alginate-Aloe vera Based Hydrogel FilmWound Healing
Published on: December 13, 2024
Austrian recommendations for the management of polycythemia vera
Sonja Burgstaller1, Veronika Buxhofer-Ausch2, Thamer Sliwa3
1Department of Internal Medicine IV, Klinikum Wels-Grieskirchen, Wels, Austria. sonja.burgstaller@klinikum-wegr.at.
Abstract:
Polycythemia vera (PV) is a clonal disease arising from hematopoietic stem cells. Erythrocytosis is the hallmark of the disease but leukocytosis, thrombocytosis and splenomegaly may also be present. Thromboembolic complications occur in about 20% of patients. Circulatory disturbances as well as pruritus represent frequent symptoms of the disease. Mutations in the JAK2 gene are present in 95% of patients in exon 14 (V617F) and in 3% in exon 12. The main goal of the treatment for patients with PV is the prevention of thromboembolic events, transformation to myelofibrosis and acute myeloid leukemia. Interferon alpha and hydroxyurea are used as first-line treatment for high risk patients. For patients unresponsive to first-line therapy ruxolitinib is available.
Related Concept Videos
Tonsillitis II: Management
Impression Management Techniques I: Managing Appearances
Managing Impressions
Management of Insomnia
Cystic Fibrosis: Management
Sinus disease and chronic...
Angina IV: Management

